CN104803978A - 一种埃索美拉唑镁的制备方法 - Google Patents
一种埃索美拉唑镁的制备方法 Download PDFInfo
- Publication number
- CN104803978A CN104803978A CN201510121344.2A CN201510121344A CN104803978A CN 104803978 A CN104803978 A CN 104803978A CN 201510121344 A CN201510121344 A CN 201510121344A CN 104803978 A CN104803978 A CN 104803978A
- Authority
- CN
- China
- Prior art keywords
- mercaptobenzimidazole
- methoxyl group
- ratio
- volume
- quality
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000197 esomeprazole magnesium Drugs 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- KWORUUGOSLYAGD-WLHYKHABSA-N magnesium;5-methoxy-2-[(r)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Chemical compound [Mg+2].C([S@@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-WLHYKHABSA-N 0.000 title abstract 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 123
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 36
- LCJDHJOUOJSJGS-UHFFFAOYSA-N 2-(chloromethyl)-4-methoxy-3,5-dimethylpyridin-1-ium;chloride Chemical compound Cl.COC1=C(C)C=NC(CCl)=C1C LCJDHJOUOJSJGS-UHFFFAOYSA-N 0.000 claims abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 64
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 44
- KWORUUGOSLYAGD-YPPDDXJESA-N esomeprazole magnesium Chemical compound [Mg+2].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-YPPDDXJESA-N 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 30
- 238000003756 stirring Methods 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 26
- 238000007670 refining Methods 0.000 claims description 24
- CRGZYKWWYNQGEC-UHFFFAOYSA-N magnesium;methanolate Chemical compound [Mg+2].[O-]C.[O-]C CRGZYKWWYNQGEC-UHFFFAOYSA-N 0.000 claims description 19
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 claims description 16
- 238000010792 warming Methods 0.000 claims description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 239000012074 organic phase Substances 0.000 claims description 12
- 239000003513 alkali Substances 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 claims description 9
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 230000003287 optical effect Effects 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 6
- FKGFUFKZUWIHFS-UHFFFAOYSA-N 4-methoxypyridine;hydrochloride Chemical compound Cl.COC1=CC=NC=C1 FKGFUFKZUWIHFS-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 4
- 229940095064 tartrate Drugs 0.000 claims description 4
- 239000010936 titanium Substances 0.000 claims description 4
- 229910052719 titanium Inorganic materials 0.000 claims description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims description 3
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 claims description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 229940126409 proton pump inhibitor Drugs 0.000 abstract description 5
- 239000000612 proton pump inhibitor Substances 0.000 abstract description 5
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 238000009833 condensation Methods 0.000 abstract description 2
- 230000005494 condensation Effects 0.000 abstract description 2
- 238000002425 crystallisation Methods 0.000 abstract description 2
- 230000008025 crystallization Effects 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract description 2
- KOFBRZWVWJCLGM-UHFFFAOYSA-N 5-methoxy-1,3-dihydrobenzimidazole-2-thione Chemical compound COC1=CC=C2NC(S)=NC2=C1 KOFBRZWVWJCLGM-UHFFFAOYSA-N 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 238000005265 energy consumption Methods 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 18
- 239000012071 phase Substances 0.000 description 14
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 11
- 229960004770 esomeprazole Drugs 0.000 description 9
- FOFFPEFVSRGLOZ-JIDHJSLPSA-N potassium;5-methoxy-2-[(s)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Chemical compound [K+].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C FOFFPEFVSRGLOZ-JIDHJSLPSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229960000496 esomeprazole sodium Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940112641 nexium Drugs 0.000 description 1
- -1 omeprazole thioether Chemical class 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510121344.2A CN104803978B (zh) | 2015-03-19 | 2015-03-19 | 一种埃索美拉唑镁的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510121344.2A CN104803978B (zh) | 2015-03-19 | 2015-03-19 | 一种埃索美拉唑镁的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104803978A true CN104803978A (zh) | 2015-07-29 |
CN104803978B CN104803978B (zh) | 2019-06-18 |
Family
ID=53689210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510121344.2A Active CN104803978B (zh) | 2015-03-19 | 2015-03-19 | 一种埃索美拉唑镁的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104803978B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106632256A (zh) * | 2016-11-24 | 2017-05-10 | 河南师范大学 | 一种质子泵抑制剂的合成方法 |
CN109705092A (zh) * | 2018-12-24 | 2019-05-03 | 湖南千金湘江药业股份有限公司 | 一种埃索美拉唑镁固体的制备方法 |
CN111116558A (zh) * | 2020-01-14 | 2020-05-08 | 常州大学 | 一种由六齿配体催化制备右旋兰索拉唑的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102993184A (zh) * | 2013-01-08 | 2013-03-27 | 湖南方盛制药股份有限公司 | 一种埃索美拉唑及其镁盐三水合物的制备方法 |
CN103265528A (zh) * | 2013-05-10 | 2013-08-28 | 湖南千金湘江药业股份有限公司 | 埃索美拉唑镁的制备方法 |
CN103709143A (zh) * | 2013-12-11 | 2014-04-09 | 开封明仁药业有限公司 | 埃索美拉唑及其镁盐的制备方法 |
-
2015
- 2015-03-19 CN CN201510121344.2A patent/CN104803978B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102993184A (zh) * | 2013-01-08 | 2013-03-27 | 湖南方盛制药股份有限公司 | 一种埃索美拉唑及其镁盐三水合物的制备方法 |
CN103265528A (zh) * | 2013-05-10 | 2013-08-28 | 湖南千金湘江药业股份有限公司 | 埃索美拉唑镁的制备方法 |
CN103709143A (zh) * | 2013-12-11 | 2014-04-09 | 开封明仁药业有限公司 | 埃索美拉唑及其镁盐的制备方法 |
Non-Patent Citations (1)
Title |
---|
孙利民 等: "第186页图3", 《埃索美拉唑镁的合成工艺的改进》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106632256A (zh) * | 2016-11-24 | 2017-05-10 | 河南师范大学 | 一种质子泵抑制剂的合成方法 |
CN109705092A (zh) * | 2018-12-24 | 2019-05-03 | 湖南千金湘江药业股份有限公司 | 一种埃索美拉唑镁固体的制备方法 |
CN111116558A (zh) * | 2020-01-14 | 2020-05-08 | 常州大学 | 一种由六齿配体催化制备右旋兰索拉唑的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104803978B (zh) | 2019-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103570686B (zh) | 一种埃索美拉唑钠的合成及精制工艺 | |
CN103664709B (zh) | 一种2-丙烯酰胺基-2-甲基丙磺酸的生产方法 | |
CN102993181B (zh) | 埃索美拉唑的制备方法及埃索美拉唑盐的制备方法 | |
CN107488139B (zh) | 一种含硫3-芳亚甲基异吲哚啉酮衍生物制备方法 | |
CN101805284B (zh) | 一种制备苯磺酸左旋氨氯地平的方法 | |
CN103936714A (zh) | 一种埃索美拉唑镁的制备方法 | |
CN104803978A (zh) | 一种埃索美拉唑镁的制备方法 | |
CN105130950A (zh) | 一种双酰胺取代的新型杯芳烃冠醚化合物及其合成方法与应用 | |
CN103265528A (zh) | 埃索美拉唑镁的制备方法 | |
CN105949118B (zh) | 一种2-芳基喹啉衍生物的制备方法 | |
CN102241670B (zh) | 一种高纯度手性亚砜类化合物的制备方法 | |
CN104774174B (zh) | 一种不对称合成s‑卡比沙明的方法 | |
CN101597277B (zh) | S-泮托拉唑及盐的制备方法 | |
CN102863361A (zh) | 甲砜霉素的手性催化合成方法 | |
CN108003048A (zh) | 一种o-甲基-苏/酪氨酸的制备方法 | |
CN103694223A (zh) | 一种一锅法制备埃索美拉唑镁的方法 | |
CN113336764B (zh) | 一类具有轴手性的联吡啶类配体及其合成方法 | |
CN103387528B (zh) | N-甲基-2(2-羟乙基)吡咯烷的拆分方法及应用 | |
CN102391126A (zh) | 一种同时生产2,4-二硝基苯甲醚和2,4-二硝基苯酚的方法 | |
CN101343248B (zh) | 一种盐酸多奈哌齐关键中间体的精制方法 | |
CN112645813B (zh) | 一种(r)-3-环己烯甲酸的制备方法 | |
CN105085487B (zh) | 一种埃索美拉唑镁三水合物的制备方法 | |
CN105585518B (zh) | 一种吉米沙星中间体的制备方法 | |
CN107715909A (zh) | 一种季戊四醇支载的脯氨酸催化剂及其制备方法及应用 | |
CN104974059B (zh) | 一种利伐沙班中间体及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
CB02 | Change of applicant information |
Address after: 272073 Shandong city of Jining province high tech Zone Shixian Road No. 1688 Applicant after: AMICOGEN (CHINA) BIOPHARM CO.,LTD. Address before: 272073 Shandong city of Jining province Shixian Road No. 1688 Applicant before: SHANDONG LUKANG RECORD PHARMACEUTICALS Co.,Ltd. |
|
COR | Change of bibliographic data | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of esomeprazole magnesium Effective date of registration: 20231027 Granted publication date: 20190618 Pledgee: Bank of Communications Ltd. Jining branch Pledgor: AMICOGEN (CHINA) BIOPHARM CO.,LTD. Registration number: Y2023980063066 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |